In the present study, a novel series of 2-(2-(3-aryl-5-substituted-1,3,4-thiadiazol-2(3H)-ylidene)hydrazinyl)-4,4-diphenyl-1H-imidazol-5(4H)-one derivatives were designed and prepared via the reaction of the most versatile, hitherto unreported 2-(5-oxo-4,4-diphenyl-4,5-dihydro-1H-imidazol-2-yl)-N-phenylhydrazinecarbothioamide with the appropriate hydrazonoyl halides. In addition, some thiazole derivatives were prepared. The structures of the newly synthesized compounds were established based on spectroscopic evidences and their alternative syntheses. Some of the newly synthesized compounds have been evaluated for their anticancer activity against a liver carcinoma cell line HEPG2-1. Moreover, their structure–activity relationship (SAR) was explored for further development in this area. The results indicated that many of the tested compounds showed moderate to high anticancer activity with respective to doxorubicin as a reference drug. Consequently, the new synthesized series of thiadiazole–imidazole derivatives are considered as powerful anticancer agents.
本研究中,设计并合成了一系列新型2-(2-(3-芳基-5-取代-1,3,4-
噻二唑-2(3H)-亚基)酰
肼基)-4,4
-二苯基-1H-咪唑-5(4H)-酮衍
生物,其合成方法是通过将迄今未报道的最通用的2-(5-氧-4,4
-二苯基-4,5-二氢-
1H-咪唑-2-基)-N-苯基酰
肼硫脲与适当的酰
肼基卤化物反应。此外,还合成了一些
噻唑衍
生物。新合成化合物的结构基于光谱证据及其替代合成方法进行确定。其中一些新合成化合物已针对肝癌HE
PG2-1
细胞系评估了其抗癌活性。此外,探讨了它们的构效关系(
SAR),为进一步开发该领域提供依据。结果表明,许多测试化合物显示出中等到高
水平的抗癌活性,相对于参考药物
阿霉素。因此,新合成的一系列
噻二唑-
咪唑衍
生物被认为是强效的抗癌剂。